Clinical Trial Update: The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients [Phase 2]

View source ↗

Summary

Update on a Phase 2 trial evaluating the effect and safety of Thymoglobulin in primary cardiac transplant recipients, currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Transplantation

Drugs mentioned

• Thymoglobulin (rabbit anti-thymocyte globulin)

Snippet

Sponsor: Cedars-Sinai Medical Center | Conditions: Heart Transplantation | Phase 2 | Status: ENROLLING_BY_INVITATION